ClinicalTrials.gg
CompletedNCT07519265Updated Sep 23, 2026

Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets

An interventional study of Chiglitazar/Metformin extended-release fixed-dose combination tablet, dose 1 and Chiglitazar tablet, dose 1 in T2DM (Type 2 Diabetes Mellitus), sponsored by Chipscreen Biosciences, Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Chipscreen Biosciences, Ltd. · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 909 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 228 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Enrollment
560th of 767
64 · median 199
Started
2026
with 87 others
No phase
194 of 909
56 open now
Registered
819th of 909
by date

Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 560th largest by enrollment of the 767 interventional ones that give a count, is one of 88 that started in 2026, is one of 194 with no phase, and was the 819th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 909 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

This is a single-center, randomized, open-label, two-period, two-sequence crossover bioequivalence study under fed conditions. The primary objective is to evaluate the bioequivalence of a single oral dose of the test formulation compared with the reference formulation in the fed state.

03

Conditions studied

  • T2DM (Type 2 Diabetes Mellitus)
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female participants;
  • Age from 18 to 45 years, inclusive;
  • (BMI) between 19.0 and 26.0 kg/m² (inclusive). Male participants must weigh at least 50.0 kg, and female participants must weigh at least 45.0 kg;
  • From the time of signing the form until 3 months after the last dose, participants must have no plans for pregnancy or sperm donation and must be willing to use effective measures;
  • Voluntarily agrees to participate in the study and signs the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Any abnormalities in laboratory tests or a history of clinically significant diseases, including but not limited to cardiovascular, cerebrovascular, hepatic, renal, respiratory, gastrointestinal, neurological, hematological, immune, oncological, psychiatric, or endocrine/metabolic disorders;
  • Known history of severe allergies (e.g., allergy to more than 3 allergens, allergies affecting the lower respiratory tract such as allergic asthma, allergies requiring treatment) or a known history of allergy to any component of the products;
  • Previous surgery that could affect drug absorption, distribution, metabolism, or excretion (e.g., subtotal gastrectomy), or a history of gastrointestinal, hepatic, or renal disease within the last 6 months that could affect drug absorption or metabolism;
  • Surgery within 3 months prior to screening or planned surgery during the study period;
  • Received any vaccination within 1 month prior to screening or plan to receive any vaccination during the study period;
  • History of infectious disease treated with significant use of antibiotics within 3 months before the first dose, or any infectious disease within 7 days before the first dose;
  • Presence of gastrointestinal symptoms (e.g., diarrhea, constipation, nausea, vomiting) within 7 days before the first dose, which the investigator deems unsuitable for study participation;
  • Use of any prescription drugs, over-the-counter drugs, or Chinese herbal medicines within 1 month before the first dose; or use of vitamin products within 2 weeks before enrollment;
  • History of drug or substance abuse, or a positive alcohol or urine drug screening test;
  • Intolerance to venipuncture, or a history of fainting in response to needles or blood;
  • Fasting blood glucose > 6.1 mmol/L or \< 3.9 mmol/L at screening, and/or a history of hypoglycemia/syncope;
  • Participation in any interventional clinical trial within 3 months prior to screening;
  • Blood donation or significant blood loss (> 200 mL) within 3 months prior to screening;
  • Pregnant or lactating women;
  • Weekly alcohol consumption of more than 14 units within 3 months prior to screening, consumption of alcohol within 48 hours before the first dose, or inability to abstain from alcohol during the study;
  • Smokes more than 5 cigarettes per day within 3 months prior to screening, has smoked within 48 hours before the first dose, or is unable to abstain from smoking during the study;
  • Excessive daily consumption of tea, coffee, and/or caffeinated beverages within 3 months prior to screening, or consumption of such beverages within 48 hours before the first dose;
  • Consumption of grapefruit or grapefruit-related citrus fruits (e.g., Seville oranges, pomelos), star fruit, papaya, pomegranate, or their products within 14 days before the first dose;
  • (GFR) \< 90 mL/min/1.73 m²;
  • Systolic blood pressure \< 90 mmHg or ≥ 140 mmHg, or diastolic blood pressure \< 50 mmHg or ≥ 90 mmHg at screening;
  • A positive test result at screening for any of the following: antibody, Treponema pallidum antibody, surface antigen, or virus antibody;
  • Inability to comply with the standardized diet (e.g., intolerance to the high-fat meal, lactose intolerance) or has difficulty swallowing;
  • Plans to or is required to engage in strenuous physical activity or exercise during the study period;
  • Any other condition that, in the opinion of the investigator, makes the participant unsuitable for inclusion in the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Sequence T-R (dose 1)

    Participants will receive Chiglitazar/Metformin extended-release fixed dose combination tablets at dose level 1 in Period 1 on Day 1, followed by Chiglitazar tablets and Metformin extended-release tablets at dose level 1 in Period 2 on Day 1.

    Drug: Chiglitazar/Metformin extended-release fixed-dose combination tablet, dose 1 · Drug: Chiglitazar tablet, dose 1 · Drug: Metformin extended-release tablet, dose 1

  • Experimental
    Sequence R-T (dose 1)

    Participants receive chiglitazar tablet and metformin extended-release tablet at dose level 1 in Period 1 on Day 1, followed by chiglitazar/metformin extended-release fixed-dose combination tablet at dose level 1 in Period 2 on Day 1.

    Drug: Chiglitazar/Metformin extended-release fixed-dose combination tablet, dose 1 · Drug: Chiglitazar tablet, dose 1 · Drug: Metformin extended-release tablet, dose 1

  • Experimental
    Sequence T-R (dose 2)

    Participants receive chiglitazar/metformin extended-release fixed-dose combination tablet at dose level 2 in Period 1 on Day 1, followed by chiglitazar tablet and metformin extended-release tablet at dose level 2 in Period 2 on Day 1.

    Drug: Chiglitazar/Metformin extended-release fixed-dose combination tablet, dose 2 · Drug: Chiglitazar tablet, dose 2 · Drug: Metformin extended-release tablet, dose 2

  • Experimental
    Sequence R-T (dose 2)

    Participants receive chiglitazar tablet and metformin extended-release tablet at dose level 2 in Period 1 on Day 1, followed by chiglitazar/metformin extended-release fixed-dose combination tablet at dose level 2 in Period 2 on Day 1.

    Drug: Chiglitazar/Metformin extended-release fixed-dose combination tablet, dose 2 · Drug: Chiglitazar tablet, dose 2 · Drug: Metformin extended-release tablet, dose 2

Interventions

  • DrugChiglitazar/Metformin extended-release fixed-dose combination tablet, dose 1

    Fixed-dose combination tablet containing chiglitazar and metformin extended-release, administered at dose level 1.

  • DrugChiglitazar tablet, dose 1

    Chiglitazar tablet administered as one of the reference treatment at dose level 1.

  • DrugMetformin extended-release tablet, dose 1

    Metformin extended-release tablet administered as one of the reference treatment at dose level 1.

  • DrugChiglitazar/Metformin extended-release fixed-dose combination tablet, dose 2

    Fixed-dose combination tablet containing chiglitazar and metformin extended-release, administered at dose level 2.

  • DrugChiglitazar tablet, dose 2

    Chiglitazar tablet administered as one of the reference treatment at dose level 2.

  • DrugMetformin extended-release tablet, dose 2

    Metformin extended-release tablet administered as one of the reference treatment at dose level 2.

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration (Cmax)

    Time frame: Pre-dose and at multiple timepoints post-dose up to 72 hours

  2. Area Under the Plasma Concentration-Time Curve from time zero to the last measurable concentration (AUC0-last)

    Time frame: Pre-dose and at multiple timepoints post-dose up to 72 hours

  3. Area Under the Plasma Concentration-Time Curve from time zero to infinity (AUC0-∞)

    Time frame: Pre-dose and at multiple timepoints post-dose up to 72 hours

Secondary outcomes

  1. Time to Maximum Plasma Concentration(Tmax)

    Time frame: Pre-dose and at multiple timepoints post-dose up to 72 hours

  2. Elimination Half-life (t1/2)

    Time frame: Pre-dose and at multiple timepoints post-dose up to 72 hours

  3. Apparent Total Clearance (CL/F)

    Time frame: Pre-dose and at multiple timepoints post-dose up to 72 hours

  4. Apparent Volume of Distribution during the terminal phase (Vz/F)

    Time frame: Pre-dose and at multiple timepoints post-dose up to 72 hours

  5. Incidence of Adverse Events (AEs)

    Time frame: up to Day 11

07

Study locations

1 site
  • Beijing Ditan Hospital, Capital Medical University
    Beijing, Beijing Municipality 101300, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2026 to primary completion in Aug 2026, 0 months.

Of 177 industry-sponsored interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 29. This study's 0 months is below that.

Counting every sponsor, half of 2,245 studies reached it within 21 months; a quarter within 10 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2026
First posted
Apr 9, 2026
StartActual
Jul 9, 2026
Primary completionActual
Aug 3, 2026
CompletionActual
Aug 3, 2026
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07519265
Responsible party
Sponsor
First posted
Apr 9, 2026
Start date
Jul 9, 2026
Primary completion
Aug 3, 2026
Completion
Aug 3, 2026
Last update
Sep 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion